A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mesothelioma
- Focus Pharmacogenomic; Therapeutic Use
- 01 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated